🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

KLF4 Epigenetic Modulation

Recruitingn/aAges 18 Years - anyAllAzienda USL Reggio Emilia - IRCCS
NCT07901335 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study investigates the epigenetic regulation of KLF4 during the progression from colorectal polyps to adenomas and carcinomas. Quantitative KLF4 methylation will be assessed in colorectal tissue samples obtained during routine colonoscopy, together with KLF4 gene expression and its correlation with methylation status in matched tissue samples. The study will also evaluate quantitative and site-specific molecular approaches for the assessment of KLF4 methylation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients undergoing routine colonoscopy * \> 18 years of age * Diagnosed by S.C. Anatomia Patologica, AUSL-IRCCS Reggio Emilia Exclusion Criteria: * Concomitant diagnosis of colorectal carcinoma
💊

What it tests

  • Not listed
📍

Where

1 site
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy